Abstract
Febrile neutropenia (FN) is associated with a significant incidence of complications, the most serious of which are listed in Table 3.1. These complications occur in about 10 % of patients with FN and are more frequent in patients with bacteremia (20 %). In addition to these complications, which often require vigorous and prolonged therapy, there are indirect and less well-measurable consequences of FN, such as possible reduction of efficacy of chemotherapy through reduction of doses or delays of administration, psychosocial burden to the patient and their family as well as social and financial cost.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer Risk Index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038-3051.
Klastersky J, Ameye L, Maertens, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30(Suppl 1):S51-S59.
Paesmans M, Klastersky J, Maertens J, et al. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter? Support Care Cancer. 2011;19:1001-1008.
McCabe WR, Jackson GG. Gram-negative bacteremia. Int Arch Med. 1962;110:92-100.
Bodey GP, Buckley M, Sathe Y, et al. Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1996;64:328-340.
Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992;10:316-322.
Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) Risk Index: ten years of use identifying low-risk febrile neutropenic cancer patients. Support Care Cancer. 2013;21:1487-1495.
Pun Hui E, Leung KS, Poon T, et al. Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. Support Care Cancer. 2011;19:1625-1635.
Cherif H, Johansson E, Bjorkholm M, et al. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica. 2006;91:215-222.
Baskaran ND, Gan GG, Adeeba K. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients. Ann Hematol. 2008;87:563-569.
Carmona-Bayonas A, Gómez J, González-Billalabeitia E, et al. Prognostic evaluation of febrile neutropaenia in apparently stable adult cancer patient. Br J Cancer. 2011;105:612-617.
Uys A, Rapoport B, Anderson R. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk index score. Support Care Cancer. 2004;12:555-560.
Innes H, Lim S, Hall A, et al. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer. 2008;16:485-4941.
Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol. 2006;24:4129-4134.
Uys A, Rapoport B, Meyer P, et al. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1β, -6 and -10. Eur J Cancer Care. 2007;16:475-483.
Santolaya ME, Alvarez AM, Aviles CL, et al. Admission clinical and laboratory factors associated with death in children with cancer during a febrile neutropenic episode. Pediatr Infect Dis J. 2007;26:794-798.
Marti F, Cullen MH, Roila F. Management of febrile neutropenia: ESMO clinical recommendations. Ann Oncol. 2009;20:iv166-iv69.
Freifeld A, Bow E, Sepkowitz K, et al. Executive summary: clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by infectious diseases society of America. Clin Infect Dis. 2011;52:e56-e93.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2014 Springer Healthcare
About this chapter
Cite this chapter
Klastersky, J.A. (2014). Prediction of the Risk of Complications Associated with Febrile Neutropenia. In: Febrile Neutropenia. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-907673-70-2_3
Download citation
DOI: https://doi.org/10.1007/978-1-907673-70-2_3
Published:
Publisher Name: Springer Healthcare, Tarporley
Print ISBN: 978-1-907673-69-6
Online ISBN: 978-1-907673-70-2
eBook Packages: MedicineMedicine (R0)